Long-term remission of TP53-mutated therapy-related acute myeloid leukaemia following allogeneic stem cell transplantation in a heart transplant recipient: A case report and literature review
Annie Xiao
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA
Search for more papers by this authorRachel Davidians
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA
Search for more papers by this authorCorresponding Author
Monzr M. Al Malki
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA
Correspondence
Monzr M. Al Malki, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, 1500 E Duarte Rd, Duarte, CA 91010, USA.
Email: [email protected]
Search for more papers by this authorAnnie Xiao
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA
Search for more papers by this authorRachel Davidians
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA
Search for more papers by this authorCorresponding Author
Monzr M. Al Malki
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA
Correspondence
Monzr M. Al Malki, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, 1500 E Duarte Rd, Duarte, CA 91010, USA.
Email: [email protected]
Search for more papers by this author
Open Research
DATA AVAILABILITY STATEMENT
For original data, please contact [email protected].
REFERENCES
- 1Doney KC, Mielcarek M, Stewart FM, Appelbaum FR. Hematopoietic cell transplantation after solid organ transplantation. Biol Blood Marrow Transplant. 2015; 21(12): 2123–2128.
- 2El Jurdi N, DeFor T, Adamusiak AM, Brunstein CG, Pruett T, Weisdorf DJ. Hematopoietic cell and solid organ transplantation in the same patient: long-term experience at the University of Minnesota: combined hematopoietic and solid organ transplantation. Biol Blood Marrow Transplant. 2020; 27: 87.e1–87.e6.
- 3Gupta M, Levine M, Porter DL, Bo-Subait S, Shaw BE, Brazauskas R, et al. Hematopoietic cell transplantation (HCT) followed by solid organ transplantation (SOT) and SOT followed by HCT: a descriptive analysis of patients undergoing sequential transplantation in the United States. Biol Blood Marrow Transplant. 2020; 26(3): S145–S146.
- 4Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020; 38(12): 1273–1283.
- 5Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020; 4(21): 5580–5588.
- 6Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, et al. Azacitidine post-transplant maintenance improves disease progression in high-risk acute myeloid leukemia and myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk. 2024; 24(5): e196–e204.
- 7Opelz G, Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation. N Engl J Med. 1994; 330(12): 816–819.
- 8Barten MJ, Schulz U, Beiras-Fernandez A, Berchtold-Herz M, Boeken U, Garbade J, et al. The clinical impact of donor-specific antibodies in heart transplantation. Transplant Rev. 2018; 32: 207–217.
- 9Lister J, Simpson JK, DeMagalhaes-Silverman MM, Rybka WB, Donnenberg AD, Myers DJ, et al. Allogeneic peripheral blood stem cell transplant for myelodysplasia after chemotherapy for post-transplant lymphoma in a cardiac transplant recipient at 10 years. Bone Marrow Transplant. 1997; 19(9): 943–945.
- 10Kobbe G, Germing U, Aivado M, Zohren F, Schubert D, Strupp C, et al. Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantation. Transplantation. 2002; 74(8): 1198–1200.
- 11Mangat JS, Rao K, Kingston J, Veys P, Amrolia P, Burch M. Early pediatric anthracycline cardiotoxicity: managed by serial heart and bone marrow transplantation. J Heart Lung Transplant. 2007; 26(6): 658–660.
- 12Schechter-Finkelstein T, Gassas A, Weitzman S, Grant D, Pollock-Barziv S, Dipchand A, et al. Hematopoietic stem-cell transplantation following solid-organ transplantation in children. Bone Marrow Transplant. 2011; 46(10): 1321–1325.
- 13Basak GW, Wiktor-Jedrzejczak W, Labopin M, Schoemans H, Ljungman P, Kobbe G, et al. Allogeneic hematopoietic stem cell transplantation in solid organ transplant recipients: a retrospective, multicenter study of the EBMT. Am J Transplant. 2015; 15(3): 705–714.
- 14Phelan R, Smith AR, Orchard PJ, Ameduri RK. Successful hematopoietic cell transplantation following cardiac transplantation in two pediatric patients. Pediatr Transplant. 2018; 22(2):e13103.
- 15Woolbright WC, Wong V, Severson E, Kuo DJ. The application of next-generation sequencing tumor molecular profiling in the diagnosis and management of a case of acute myelogenous leukemia with MLL-Ptd in a pediatric heart transplant recipient. J Pediatr Hematol Oncol. 2021; 43(2): e246–e249.
- 16Ueda T, Fujita J, Akazawa Y, Kawamura A, Matsui T, Hino A, et al. Successful bridging to allogeneic hematopoietic stem cell transplantation by azacitidine and venetoclax in a case of acute myeloid leukemia with t(3;3)(q21.3;q26.2) developed early after orthotopic heart transplantation. Transplant Proc. 2023; 55(3): 711–714.
Citing Literature
